<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235179</url>
  </required_header>
  <id_info>
    <org_study_id>E-19-4466</org_study_id>
    <nct_id>NCT04235179</nct_id>
  </id_info>
  <brief_title>Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer (ASPIRE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 30 Gy in 5
      fractions, once weekly to the pelvis in post operative patients with endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Treatment-Related Adverse Events</measure>
    <time_frame>3 months after accrual is completed</time_frame>
    <description>The number of participants with acute (&lt;3 months) urinary and bowel treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Treatment-Related Adverse Events</measure>
    <time_frame>5 years after accrual is completed</time_frame>
    <description>The number of participants with late (&gt;3 months) urinary and bowel treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Local-Regional Failure Rate</measure>
    <time_frame>5 years after accrual is completed</time_frame>
    <description>The rate of local-regional failure of the disease in participants after adjuvant SABR treatment in the setting of high-risk endometrial cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years after accrual is completed</time_frame>
    <description>The mean decrease in Quality of Life in participants after adjuvant SBRT treatment using EORTC (European Organisation for Research and Treatment of Cancer) core questionnaire (QLQ-C30) with EN-24 companion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>SABR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pelvic SABR for post-op endometrial cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SABR</intervention_name>
    <description>SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)</description>
    <arm_group_label>SABR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histologically confirmed endometrial adenocarcinoma

          -  Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy),
             meeting one of the following conditions: High grade histology OR Outer-half myometrial
             invasion with any risk factors OR FIGO stage II - IIIC1.

          -  Age â‰¥18 years.

          -  Patients who are to receive adjuvant systemic therapy in addition to pelvic
             radiotherapy will be eligible provided that there is at minimum a 3-week interval
             between any radiation treatment and chemotherapy treatments.

        Exclusion Criteria:

          -  Patient has had prior pelvic radiotherapy.

          -  Patient has Type II endometrial cancer histology (ie. Serous, clear cell or
             carcinosarcoma).

          -  Patient has a contraindication to pelvic radiotherapy, such as but not limited to a
             connective tissue disease or inflammatory bowel disease.

          -  Patient has a contraindication to CT contrast.

          -  Patient has a hip prosthesis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King Saud University Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasir Alayed, MD</last_name>
      <phone>+966114671546</phone>
      <email>yalayed@ksu.edu.sa</email>
    </contact>
    <investigator>
      <last_name>Yasir Alayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>January 19, 2020</last_update_submitted>
  <last_update_submitted_qc>January 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Dr. Yasir Alayed</investigator_full_name>
    <investigator_title>Consultant and Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

